The READ Trial investigates the impact of Dapagliflozin (an SGLT2 inhibitor) + calorie restriction on diabetes remission in overweight/obese patients with Type 2 Diabetes. This episode discusses:

• The role of SGLT2 inhibitors in metabolic regulation
• How calorie restriction enhances diabetes remission
• Study results on HbA1c reduction, weight loss, and metabolic benefits
• Whether Dapagliflozin should be integrated into diabetes remission protocols

The SUGAR-DIP Trial examines whether a sequential oral medication strategy (Metformin + Glyburide) is non-inferior to insulin for preventing large-for-gestational-age (LGA) infants in gestational diabetes. This episode explores:

• The efficacy of oral agents vs. insulin in glycemic control
• Differences in neonatal outcomes, maternal hypoglycemia, and birth complications
• Why insulin remains the gold standard in gestational diabetes
• Future prospects for oral therapy in pregnancy

The REGENCY Trial evaluates Obinutuzumab, a type II anti-CD20 monoclonal antibody, in Class III and IV Lupus Nephritis (LN). This episode dives into:

• The mechanism of B-cell depletion therapy in lupus nephritis
• Study results comparing Obinutuzumab + standard therapy vs. standard therapy alone
• Effects on renal response, proteinuria reduction, and steroid-sparing benefits
• The future role of targeted biologics in lupus nephritis treatment